ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novel shows promise in Phase II schizophrenia trial
February 26, 2021KarXT significantly reduced both positive and negative of symptoms of schizophrenia without the common problematic side effects of current antipsychotic therapies. -
PureTech affiliate Karuna advances schizophrenia candidate
October 19, 2018Karuna Pharmaceuticals, an affiliate of UK-listed biopharma PureTech Health, has kicked off a Phase II study of KarXT, which is being developed for the treatment of psychosis in schizophrenia.
Pharma Sources Insight January 2025
